Cargando…
Regulatory challenges with biosimilars: an update from 20 countries
The World Health Organization (WHO) issued guidelines for the regulatory evaluation of biosimilars in 2009 and has provided considerable effort toward helping member states implement the evaluation principles in the guidelines into their regulatory practices. Despite this effort, a recent WHO survey...
Autores principales: | Kang, Hye‐Na, Thorpe, Robin, Knezevic, Ivana, Casas Levano, Mary, Chilufya, Mumbi Bernice, Chirachanakul, Parichard, Chua, Hui Ming, Dalili, Dina, Foo, Freddie, Gao, Kai, Habahbeh, Suna, Hamel, Hugo, Kim, Gi Hyun, Perez Rodriguez, Violeta, Putri, Desi Eka, Rodgers, Jacqueline, Savkina, Maria, Semeniuk, Oleh, Srivastava, Shraddha, Tavares Neto, João, Wadhwa, Meenu, Yamaguchi, Teruhide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247359/ https://www.ncbi.nlm.nih.gov/pubmed/33222245 http://dx.doi.org/10.1111/nyas.14522 |
Ejemplares similares
-
The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
por: Kang, Hye-Na, et al.
Publicado: (2020) -
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study
por: Thorpe, Robin, et al.
Publicado: (2019) -
WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021
por: Wadhwa, Meenu, et al.
Publicado: (2022) -
Regulatory evaluation of biosimilars throughout their product life-cycle
por: Kang, Hye-Na, et al.
Publicado: (2018) -
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience
por: Kurki, Pekka, et al.
Publicado: (2022)